SEC Form 4 · accession 0001209191-16-119856

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

May 11, 2016

Accepted (ET)

May 13, 2016 · 3:20 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	May 11, 2016	M	5,130	$35.35	A	270,414	D
Common Stock^F2,F3	May 11, 2016	S	430	$83.90	D	269,984	D
Common Stock^F2,F4	May 11, 2016	S	1,200	$85.26	D	268,784	D
Common Stock^F2,F5	May 11, 2016	S	1,600	$86.78	D	267,184	D
Common Stock^F2,F6	May 11, 2016	S	1,400	$87.43	D	265,784	D
Common Stock^F2,F7	May 11, 2016	S	500	$88.20	D	265,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F8	$35.35	May 11, 2016	M	5,130	D	—	Jul 19, 2016	Common Stock	5,130	41,050	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $83.90 (range $83.60 to $84.42).
F4Open market sales reported on this line occurred at a weighted average price of $85.26 (range $84.76 to $85.73).
F5Open market sales reported on this line occurred at a weighted average price of $86.78 (range $86.11 to $87.10).
F6Open market sales reported on this line occurred at a weighted average price of $87.43 (range $87.13 to $88.10).
F7Open market sales reported on this line occurred at a weighted average price of $88.20 (range $88.14 to $88.26).
F8Fully vested.